Golden logoGolden logo
Advanced Search
Homology Medicines

Homology Medicines

A genetic medicines company in Massachusetts that focuses on patients suffering from rare genetic diseases.

Homology Medicines is a genetic medicines company in Massachusetts that focuses on patients suffering from rare genetic diseases. Founded 2015 in Lexington, Massachusetts, United States by Laura Smith and Saswati Chatterjee, Homology’s proprietary platform is designed to utilize its human hematopoietic stem cell-derived adeno-associated virus vectors (AAVHSCs) to precisely and efficiently deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a broad range of genetic disorders. The company has a suite of 15 AAVHSC patents, including a proprietary gene editing and gene therapy platform for rare diseases.

The company has developed a novel set of adeno-associated virus vectors derived from human hematopoietic stem cells (AAVHSCs) that are designed to precisely and efficiently deliver genetic medicines in vivo either through gene therapy or by harnessing the body’s natural DNA repair process of homologous recombination through nuclease-free gene editing.

Timeline

November 9, 2020
Homology Medicines raises a $60,000,000 venture round from Pfizer.
August 2017
Homology Medicines raises a $83,500,000 series B round from 5AM Ventures, ARCH Venture Partners, Deerfield Management Company, HBM Healthcare Investments AG, Maverick Ventures, Novartis, Rock Springs Capital, Temasek Holdings, Vida Ventures and Vivo Capital.
May 2, 2016
Homology Medicines raises a $43,500,000 series A round from 5AM Ventures, ARCH Venture Partners, Deerfield Capital Management and Temasek Holdings.
June 3, 2015
Homology Medicines was founded by Laura Smith.
2015
Founded

Funding Rounds

Patents

Further Resources

Title
Author
Link
Type
Date

News

Title
Author
Date
Publisher
Description
BioSpace
June 9, 2021
BioSpace
eGenesis announced the appointment of accomplished financial executive, Bradford Smith, Chief Financial Officer of Homology Medicines, Inc., as an independent member of the Board of Directors.
BioSpace
April 12, 2021
BioSpace
Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Tim Kelly has been promoted to Chief Operating Officer, effective immediately

References

Golden logo
By using this site, you agree to our Terms of Service.